Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Diabetic lower extremity arterial disease ( DLEAD ), is a common complication of type 2
diabetes. However, DLEAD remains less studied than other diabetic vascular complications; and
only few randomised controlled trials (RCTs) have dealt with major lower-limb adverse events
as prespecified endpoints. Studies have suggested that glucagon-like peptide-1 (GLP-1)
analogues have a protective effect on the development of atherosclerosis, potentially
mediated via the GLP-1 receptors expressed on endothelial cells, smooth muscle cells, and in
monocytes/macrophages. The investigators aim to evaluate the improvement of lower extremity
ischemia in patients with type 2 diabetes mellitus complicated with lower limb vascular
lesions after liraglutide, compared with the standard-of-care treatment group.
Phase:
Phase 4
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University